News releases from Eyenovia, Inc.
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
April 01, 2021
Dr. Julia Haller brings experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader to her role as an Eyenovia director.
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
March 23, 2021
Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
March 17, 2021
Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.
Eyenovia to Participate in the 33rd Annual Roth Conference
March 10, 2021
Eyenovia Announces FDA Acceptance of the MydCombi NDA
March 02, 2021
FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
February 16, 2021
The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET
Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
January 26, 2021
Eyenovia consultant Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28.
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
January 06, 2021
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
December 29, 2020
Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
December 16, 2020
Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
December 03, 2020
Eyenovia obtains FDA acceptance of its IND application for MicroLine, a therapy designed for improvement in near vision in patients with presbyopia.
Eyenovia Reports Third Quarter 2020 Financial Results
November 10, 2020
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
November 05, 2020
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
October 13, 2020
Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting
October 05, 2020
Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
September 09, 2020
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
August 24, 2020
Eyenovia, Inc. Announces Closing of Offering of Common Stock
August 21, 2020
Eyenovia, Inc. Prices Public Offering of Common Stock
August 19, 2020
Eyenovia Reports Second Quarter 2020 Financial Results
August 12, 2020
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
August 11, 2020
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
July 29, 2020